Results of a new study have shown the enormous potential of smartphone-collected, real-world data for the differentiation of patients with Parkinson disease from controls. This study spearheads a new phase for the evaluation of symptoms associated with Parkinson disease that is patient-centred, digital, objective, continuous and relevant to everyday life.
This is a preview of subscription content
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
van den Heuvel, L. et al. Quadruple decision making for Parkinson’s disease patients: combining expert opinion, patient preferences, scientific evidence, and big data approaches to reach precision medicine. J. Parkinsons Dis. 10, 223–231 (2020).
Dorsey, E. R., Glidden, A. M., Holloway, M. R., Birbeck, G. L. & Schwamm, L. H. Teleneurology and mobile technologies: the future of neurological care. Nat. Rev. Neurol. 14, 285–297 (2018).
Omberg, L. et al. Remote smartphone monitoring of Parkinson’s disease and individual response to therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00974-9 (2021).
US Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices (2017).
Husain, M. Time for N-of-1 trials in clinical decision-making. Brain 144, 1031–1032 (2021).
Manta, C., Patrick-Lake, B. & Goldsack, J. C. Digital measures that matter to patients: a framework to guide the selection and development of digital measures of health. Digit. Biomark. 4, 69–77 (2020).
Coran, P. et al. Advancing the use of mobile technologies in clinical trials: recommendations from the clinical trials transformation initiative. Digit. Biomark. 3, 145–154 (2019).
US Food and Drug Administration. Drug development tool. Letter of intent determination. DDT COA #000142. FDA https://www.fda.gov/media/149517/download (2021).
Morgan, C. et al. Systematic Review looking at the use of technology to measure free-living symptom and activity outcomes in Parkinson’s disease in the home or a home-like environment. J. Parkinsons Dis. 10, 429–454 (2020).
The authors declare no competing interests.
About this article
Cite this article
Maetzler, W., Pilotto, A. Digital assessment at home — mPower against Parkinson disease. Nat Rev Neurol 17, 661–662 (2021). https://doi.org/10.1038/s41582-021-00567-9